Catalent (NYSE:CTLT) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Catalent (NYSE:CTLT - Free Report) from a sell rating to a hold rating in a report published on Thursday morning.

Other equities analysts have also issued research reports about the stock. Baird R W lowered shares of Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Robert W. Baird reiterated a "neutral" rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Finally, William Blair reissued a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Nine analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Catalent has a consensus rating of "Hold" and an average price target of $59.83.

Catalent Stock Performance

NYSE:CTLT traded down $0.24 during mid-day trading on Thursday, hitting $58.91. The stock had a trading volume of 1,084,760 shares, compared to its average volume of 2,037,158. Catalent has a 52 week low of $36.00 and a 52 week high of $61.20. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $10.69 billion, a price-to-earnings ratio of -26.17, a P/E/G ratio of 2.36 and a beta of 1.16. The company has a 50 day simple moving average of $59.89 and a 200-day simple moving average of $58.16.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the company earned ($0.10) earnings per share. The business's quarterly revenue was up 4.2% compared to the same quarter last year. On average, research analysts expect that Catalent will post 0.84 earnings per share for the current fiscal year.

Insider Activity

In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company's stock, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares of the company's stock, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 over the last three months. Insiders own 0.31% of the company's stock.

Hedge Funds Weigh In On Catalent

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTLT. Public Sector Pension Investment Board boosted its holdings in shares of Catalent by 16.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 7,910 shares of the company's stock worth $479,000 after buying an additional 1,100 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Catalent by 4.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,024,240 shares of the company's stock valued at $62,038,000 after acquiring an additional 45,564 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Catalent by 12.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,982 shares of the company's stock valued at $2,301,000 after purchasing an additional 4,088 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Catalent by 166.5% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company's stock worth $83,733,000 after purchasing an additional 863,624 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Catalent by 9.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 267,219 shares of the company's stock worth $16,185,000 after purchasing an additional 22,785 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.